SIGA Technologies
Developer of small-molecule antiviral medicines and related countermeasures focused on orthopoxviruses and other high-concern infectious diseases. Operates product development, preclinical and clinical safety testing, regulatory submissions across multiple jurisdictions, and manufacturing/packaging operations to supply government stockpiles and healthcare providers. Collaborates with U.S. government agencies and international regulators on development and procurement.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
TPOXX (tecovirimat)
A small-molecule antiviral indicated for treatment of smallpox and authorized/approved for use against certain orthopoxvirus infections; available as oral capsules and an intravenous formulation, with pediatric liquid suspension under development.
TPOXX
Oral TPOXX (tecovirimat capsule) is an antiviral drug indicated for treating smallpox disease, and used under expanded access for mpox, specifically inhibiting the orthopoxvirus VP37 protein.
TPOXX (tecovirimat)
A small-molecule antiviral indicated for treatment of smallpox and authorized/approved for use against certain orthopoxvirus infections; available as oral capsules and an intravenous formulation, with pediatric liquid suspension under development.
TPOXX
Oral TPOXX (tecovirimat capsule) is an antiviral drug indicated for treating smallpox disease, and used under expanded access for mpox, specifically inhibiting the orthopoxvirus VP37 protein.
Services
Collaborative development arrangements with public agencies and funders to advance medical countermeasures and support procurement to national stockpiles.
Collaborative development arrangements with public agencies and funders to advance medical countermeasures and support procurement to national stockpiles.
Expertise Areas
- Antiviral drug development
- Preclinical animal model development
- Clinical safety studies and expanded-access protocols
- Regulatory strategy and multi-jurisdictional approvals
Key Technologies
- Small-molecule antiviral therapeutics
- Orthopoxvirus animal models (for efficacy testing)
- Formulation chemistry (oral capsules, IV, liquid suspension)
- In vitro antiviral assays / drug screening
News & Updates
Oral tecovirimat capsules were approved by the U.S. FDA specifically for treatment of smallpox disease in adults and pediatric patients weighing at least 13 kg.
Oral tecovirimat authorized by Health Canada for treatment of smallpox in adults and pediatric patients weighing at least 13 kg.
Tecovirimat approved by the European Medicines Agency for treatment of smallpox, cowpox, and vaccinia complications in specified populations.
Tecovirimat capsules approved by Japan's Pharmaceuticals and Medical Devices Agency for treatment of orthopoxvirus infections including mpox and smallpox in adults and pediatric patients weighing at least 13 kg.
Product advanced to the Strategic National Stockpile and procured under Project BioShield and other government programs.
Company reports cumulative government procurement orders above $1 billion.
Oral tecovirimat capsules were approved by the U.S. FDA specifically for treatment of smallpox disease in adults and pediatric patients weighing at least 13 kg.
Oral tecovirimat authorized by Health Canada for treatment of smallpox in adults and pediatric patients weighing at least 13 kg.
Tecovirimat approved by the European Medicines Agency for treatment of smallpox, cowpox, and vaccinia complications in specified populations.
Tecovirimat capsules approved by Japan's Pharmaceuticals and Medical Devices Agency for treatment of orthopoxvirus infections including mpox and smallpox in adults and pediatric patients weighing at least 13 kg.
Product advanced to the Strategic National Stockpile and procured under Project BioShield and other government programs.
Company reports cumulative government procurement orders above $1 billion.